Stay updated on BOS-580 in NASH Obese Subjects Clinical Trial
Sign up to get notified when there's something new on the BOS-580 in NASH Obese Subjects Clinical Trial page.

Latest updates to the BOS-580 in NASH Obese Subjects Clinical Trial page
- ChecktodayChange DetectedAdded: a new Lancet article citation for Efimosfermin BOS-580 (2026). Deleted: older related topics entry and an earlier Lancet preprint citation.SummaryDifference0.2%

- Check8 days agoChange DetectedRevision on the page updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedAdded related topics: Non-alcoholic fatty liver disease and MedlinePlus Genetics. These enhancements improve discoverability and provide additional context without altering study data or core content.SummaryDifference0.1%

- Check36 days agoChange DetectedAdded a Lancet publication citation for Efimosfermin (BOS-580) in Publications and updated the page revision to v3.4.2. Removed the funding lapse notice and related topics such as Non-alcoholic fatty liver disease and MedlinePlus Genetics.SummaryDifference0.4%

- Check43 days agoChange DetectedSite-wide notices about a lapse in government funding and a version update to v3.4.1 are shown; the previous version v3.4.0 is removed. No changes to the study details, eligibility, or primary trial data are evident.SummaryDifference0.3%

- Check50 days agoChange DetectedThe page now shows a glossary and includes added terms such as Non-alcoholic fatty liver disease and MedlinePlus Genetics. It also updates revision metadata to v3.4.0 and removes older labels (e.g., No FEAR Act data and the prior revision label).SummaryDifference0.3%

Stay in the know with updates to BOS-580 in NASH Obese Subjects Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BOS-580 in NASH Obese Subjects Clinical Trial page.